Skip to main content

Advertisement

SpringerLink
Log in

Blockade of Leukocyte Function Antigen-1 (LFA-1) in Clinical Islet Transplantation

  • Clinical Trial Report
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Pileggi A, Ricordi C, Kenyon NS, Froud T, Baidal DA, Kahn A et al. Twenty years of clinical islet transplantation at the Diabetes Research Institute--University of Miami. Clin Transpl. 2004:177–204.

  2. Mineo D, Pileggi A, Alejandro R, Ricordi C. Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care. 2009;32(8):1563–9. doi:10.2337/dc09-0490.

    Article  PubMed  Google Scholar 

  3. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060–9.

    Article  PubMed  CAS  Google Scholar 

  4. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355(13):1318–30. doi:10.1056/NEJMoa061267.

    Article  PubMed  CAS  Google Scholar 

  5. Froud T, Ricordi C, Baidal DA, Hafiz MM, Ponte G, Cure P, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant. 2005;5(8):2037–46. doi:10.1111/j.1600-6143.2005.00957.x.

    Article  PubMed  Google Scholar 

  6. Pileggi A, Cobianchi L, Inverardi L, Ricordi C. Overcoming the challenges now limiting islet transplantation: a sequential, integrated approach. Ann N Y Acad Sci. 2006;1079:383–98. doi:10.1196/annals.1375.059.

    Article  PubMed  Google Scholar 

  7. Alejandro R, Barton FB, Hering BJ, Wease S. 2008 update from the collaborative islet transplant registry. Transplantation. 2008;86(12):1783–8. doi:10.1097/TP.0b013e3181913f6a.

    Article  PubMed  Google Scholar 

  8. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, et al. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010;10(8):1870–80. doi:10.1111/j.1600-6143.2010.03073.x.

    Article  PubMed  CAS  Google Scholar 

  9. Turgeon NA, Avila JG, Cano JA, Hutchinson JJ, Badell IR, Page AJ, et al. Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant. 2010;10(9):2082–91. doi:10.1111/j.1600-6143.2010.03212.x.

    Article  PubMed  CAS  Google Scholar 

  10. Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant. 2006;6(1):27–36. doi:10.1111/j.1600-6143.2005.01158.x.

    Article  PubMed  CAS  Google Scholar 

  11. Ostermann G, Weber KS, Zernecke A, Schroder A, Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol. 2002;3(2):151–8. doi:10.1038/ni755.

    Article  PubMed  CAS  Google Scholar 

  12. Berney T, Pileggi A, Molano RD, Poggioli R, Zahr E, Ricordi C, et al. The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. Transplantation. 2003;76(12):1669–74. doi:10.1097/01.TP.0000092525.17025.D0.

    Article  PubMed  CAS  Google Scholar 

  13. Badell IR, Russell MC, Thompson PW, Turner AP, Weaver TA, Robertson JM, et al. LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J Clin Invest. 2010;120(12):4520–31. doi:10.1172/JCI43895.

    Article  PubMed  CAS  Google Scholar 

  14. Gotoh M, Fukuzaki T, Monden M, Dono K, Kanai T, Yagita H, et al. A potential immunosuppressive effect of anti-lymphocyte function-associated antigen-1 monoclonal antibody on islet transplantation. Transplantation. 1994;57(1):123–6.

    PubMed  CAS  Google Scholar 

  15. Nicolls MR, Coulombe M, Beilke J, Gelhaus HC, Gill RG. CD4-dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways. J Immunol. 2002;169(9):4831–9.

    PubMed  Google Scholar 

  16. Nicolls MR, Coulombe M, Diamond AS, Beilke J, Gill RG. Interferon-gamma is not a universal requirement for islet allograft survival. Transplantation. 2002;74(4):472–7. doi:10.1097/01.TP.0000026310.54443.3E.

    Article  PubMed  CAS  Google Scholar 

  17. Nicolls MR, Coulombe M, Yang H, Bolwerk A, Gill RG. Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4. J Immunol. 2000;164(7):3627–34.

    PubMed  CAS  Google Scholar 

  18. Chowdhury SA, Nagata M, Yamada K, Nakayama M, Chakrabarty S, Jin Z, et al. Tolerance mechanisms in murine autoimmune diabetes induced by anti-ICAM-1/LFA-1 mAb and anti-CD8 mAb. Kobe J Med Sci. 2002;48(5–6):167–75.

    PubMed  CAS  Google Scholar 

  19. Hasegawa Y, Yokono K, Taki T, Amano K, Tominaga Y, Yoneda R, et al. Prevention of autoimmune insulin-dependent diabetes in non-obese diabetic mice by anti-LFA-1 and anti-ICAM-1 mAb. Int Immunol. 1994;6(6):831–8.

    Article  PubMed  CAS  Google Scholar 

  20. Ninova D, Dean PG, Stegall MD. Immunomodulation through inhibition of multiple adhesion molecules generates resistance to autoimmune diabetes in NOD mice. J Autoimmun. 2004;23(3):201–9. doi:10.1016/j.jaut.2004.07.002.

    Article  PubMed  CAS  Google Scholar 

  21. Arefanian H, Tredget EB, Rajotte RV, Korbutt GS, Gill RG, Rayat GR. Combination of anti-CD4 with anti-LFA-1 and anti-CD154 monoclonal antibodies promotes long-term survival and function of neonatal porcine islet xenografts in spontaneously diabetic NOD mice. Cell Transplant. 2007;16(8):787–98.

    PubMed  Google Scholar 

  22. Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007;7(7):1770–7. doi:10.1111/j.1600-6143.2007.01845.x.

    Article  PubMed  CAS  Google Scholar 

  23. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol. 2008;158(5):1107–16. doi:10.1111/j.1365-2133.2008.08548.x.

    Article  PubMed  CAS  Google Scholar 

  24. FDA US Food and Drug Administration: Safety: Raptiva (efalizumab) Feb 2009. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm149675.htm. Accessed July 5, 2011.

  25. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230–8. doi:10.1056/NEJM200007273430401.

    Article  PubMed  CAS  Google Scholar 

  26. Barshes NR, Lee TC, Goodpastor SE, Balkrishnan R, Schock AP, Mote A, et al. Transaminitis after pancreatic islet transplantation. J Am Coll Surg. 2005;200(3):353–61. doi:10.1016/j.jamcollsurg.2004.10.021.

    Article  PubMed  Google Scholar 

  27. Hafiz MM, Faradji RN, Froud T, Pileggi A, Baidal DA, Cure P, et al. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation. 2005;80(12):1718–28.

    Article  PubMed  CAS  Google Scholar 

  28. Rafael E, Ryan EA, Paty BW, Oberholzer J, Imes S, Senior P, et al. Changes in liver enzymes after clinical islet transplantation. Transplantation. 2003;76(9):1280–4. doi:10.1097/01.TP.0000098822.85924.4C.

    Article  PubMed  CAS  Google Scholar 

  29. Maffi P, Bertuzzi F, De Taddeo F, Magistretti P, Nano R, Fiorina P, et al. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care. 2007;30(5):1150–5. doi:10.2337/dc06-1794.

    Article  PubMed  CAS  Google Scholar 

  30. Leitao CB, Cure P, Messinger S, Pileggi A, Lenz O, Froud T, et al. Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management. Transplantation. 2009;87(5):681–8. doi:10.1097/TP.0b013e31819279a8.

    Article  PubMed  Google Scholar 

  31. Warnock GL, Thompson DM, Meloche RM, Shapiro RJ, Ao Z, Keown P, et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation. 2008;86(12):1762–6. doi:10.1097/TP.0b013e318190b052.

    Article  PubMed  Google Scholar 

  32. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293(7):830–5. doi:10.1001/jama.293.7.830.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

A. Pileggi has received grant support from the following agencies: the National Institutes of Health (5R01DK25802, 5R01DK56953, 1U01DK70460, 1R21DK076098, 5R01DK059993, 1DP2DK083096, U01DK089538, 5U42RR016603-08S1, 5U42RR016603, MO1RR16587, 1R01EB008009, and 5U19AI050864-10), the Juvenile Diabetes Research Foundation International (4-2000-946, 4-2000-947, 4-2004-361, 6-39017G1, 4-2008-811 and 17-2010-5), the State of Florida, the University of Miami Interdisciplinary Research Development Initiative, and the Diabetes Research Institute Foundation (www.DiabetesResearch.org). A contract for support of this research, sponsored by United States Congressman Bill Young and funded by a special congressional out of the US Navy Bureau of Medicine and Surgery, is presently managed by the Naval Health Research Center, San Diego, CA. The authors alone are responsible for reporting and interpreting these data; the views expressed herein are those of the authors and not necessarily those of the United States government.

Disclosure

Conflicts of interest: C. Fotino: has performed studies partially supported by Medestea Research; A. Pileggi: is a scientific advisory board member of Converge Biotech, and he has received corporate grant support from Pfizer, Positive ID, and Extended Drug Delivery.

Author information

Authors and Affiliations

  1. Diabetes Research Institute, University of Miami, 1450 NW 10th Avenue (R134), Miami, FL, 33136, USA

    Carmen Fotino & Antonello Pileggi

  2. DeWitt-Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA

    Antonello Pileggi

  3. Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA

    Antonello Pileggi

  4. Department of Biomedical Engineering, University of Miami, Miami, FL, USA

    Antonello Pileggi

Authors
  1. Carmen Fotino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonello Pileggi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonello Pileggi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fotino, C., Pileggi, A. Blockade of Leukocyte Function Antigen-1 (LFA-1) in Clinical Islet Transplantation. Curr Diab Rep 11, 337–344 (2011). https://doi.org/10.1007/s11892-011-0214-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-011-0214-y

Keywords

Search

Navigation